Celularity INC (CELUW) — SEC Filings

Overview

Celularity INC (CELUW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 31, 2025: Celularity Inc. (CELUW) is offering up to 14,078,938 shares of Class A Common Stock on a resale basis, comprising 2,531 shares, 11,732,657 shares issuable upon warrant exercise, and 2,343,750 shares from a convertible note. The company will not receive proceeds from the stock sale, but could gain ap

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Celularity INC is neutral.

Filing Type Overview

Celularity INC (CELUW) has filed 2 S-1, 36 8-K, 5 10-Q, 2 DEF 14A, 1 8-K/A, 1 10-K/A, 2 10-K, 1 S-1/A with the SEC between May 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Celularity Resale Offering Signals Capital Need Amid Pipeline Push — S-1 · Dec 31, 2025 Risk: high
  Celularity Inc. (CELUW) is offering up to 14,078,938 shares of Class A Common Stock on a resale basis, comprising 2,531 shares, 11,732,657 shares issuable upon
• Celularity Inc. Files 8-K: Material Agreements and Equity Sales — 8-K · Dec 23, 2025 Risk: medium
  On December 19, 2025, Celularity Inc. entered into a material definitive agreement and incurred a direct financial obligation. The company also reported unregis
• Celularity Inc. Files 8-K on Security Holder Vote Matters — 8-K · Dec 19, 2025 Risk: medium
  Celularity Inc. filed an 8-K on December 19, 2025, reporting on the submission of matters to a vote of security holders. The company, formerly GX Acquisition Co
• 8-K Filing — 8-K · Dec 5, 2025
• Celularity's Revenue Plummets, Losses Mount Amid Liquidity Crisis — 10-Q · Nov 14, 2025 Risk: high
  Celularity Inc. reported a significant decline in total net revenues for the nine months ended September 30, 2025, falling to $22.446 million from $36.088 milli
• Celularity Seeks Shareholder Approval for Director Re-election, Equity Plan Boost — DEF 14A · Nov 7, 2025 Risk: medium
  Celularity Inc. (CELUW) is holding its 2025 Annual Meeting of Stockholders on December 19, 2025, at its headquarters in Florham Park, New Jersey. Key proposals
• Celularity Inc. Files 8-K: Material Agreements & Equity Sales — 8-K · Oct 28, 2025 Risk: medium
  Celularity Inc. entered into a material definitive agreement on October 24, 2025. The company also reported on unregistered sales of equity securities and amend
• Celularity Inc. Files 8-K Under 'Other Events' — 8-K · Sep 3, 2025 Risk: low
  Celularity Inc. filed an 8-K on September 3, 2025, reporting an event on September 2, 2025. The filing is categorized under 'Other Events' and does not specify
• Celularity's Cash Dries Up Amidst Declining Sales, Mounting Debt — 10-Q · Aug 29, 2025 Risk: high
  Celularity Inc. (CELUW) reported a net loss of $19.754 million for the three months ended March 31, 2025, a slight improvement from the $22.013 million net loss
• Celularity Inc. Files 8-K: Material Definitive Agreement — 8-K · Aug 18, 2025 Risk: medium
  Celularity Inc. entered into a Material Definitive Agreement on August 13, 2025. The filing also includes other events and financial statements/exhibits. Celula
• Celularity Inc. Files 8-K: Material Definitive Agreement — 8-K · Aug 12, 2025 Risk: medium
  Celularity Inc. entered into a material definitive agreement on August 5, 2025. The company, formerly known as GX Acquisition Corp., is incorporated in Delaware
• Celularity Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Aug 1, 2025 Risk: medium
  On July 21, 2025, Celularity Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported on the cr
• Celularity Inc. Files 8-K on Material Agreement and Equity Sales — 8-K · Jul 30, 2025 Risk: medium
  Celularity Inc. filed an 8-K on July 30, 2025, reporting on events that occurred on July 14, 2025. The filing indicates an entry into a material definitive agre
• Celularity Inc. Files 8-K/A Amendment — 8-K/A · Jul 29, 2025 Risk: low
  Celularity Inc. filed an amendment (8-K/A) on July 29, 2025, to its report originally dated February 12, 2025. This amendment pertains to financial statements a
• Celularity Inc. Files 8-K for Material Agreement — 8-K · Jul 22, 2025 Risk: medium
  Celularity Inc. entered into a material definitive agreement on June 23, 2025, related to unregistered sales of equity securities. The filing also includes fina
• Celularity Inc. Files 8-K: Board Changes & Compensation Updates — 8-K · Jun 10, 2025 Risk: medium
  Celularity Inc. announced on June 10, 2025, changes in its board of directors and executive compensation arrangements. The filing also includes financial statem
• Celularity Inc. Reports Board and Executive Compensation Changes — 8-K · Jun 6, 2025 Risk: medium
  Celularity Inc. announced on June 5, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the de
• Celularity Inc. Files 2024 Annual Report Amendment — 10-K/A · May 21, 2025 Risk: medium
  Celularity Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly GX Acquisition Corp., is inc
• Celularity Inc. Files 8-K on Material Agreements — 8-K · May 20, 2025 Risk: medium
  On May 20, 2025, Celularity Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The company, formerl
• Celularity Inc. Announces Board and Executive Compensation Changes — 8-K · May 16, 2025 Risk: medium
  Celularity Inc. announced on May 14, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certai
• Celularity Inc. Files 8-K on Financials — 8-K · May 9, 2025 Risk: low
  Celularity Inc. filed an 8-K on May 9, 2025, reporting on its results of operations and financial condition, and providing financial statements and exhibits. Th
• Celularity Inc. Files 2024 10-K — 10-K · May 8, 2025 Risk: medium
  Celularity Inc. filed its 2024 10-K on May 8, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly GX Acquisition Corp., is involv
• Celularity Inc. Updates Principal Executive Offices — 8-K · May 1, 2025 Risk: low
  Celularity Inc. filed an 8-K on May 1, 2025, reporting an event on April 30, 2025. The filing indicates a change in the company's principal executive offices to
• Celularity Inc. Faces Delisting Concerns — 8-K · Apr 23, 2025 Risk: high
  Celularity Inc. filed an 8-K on April 23, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was
• Celularity Inc. Files 8-K for Material Agreement — 8-K · Mar 21, 2025 Risk: medium
  On March 17, 2025, Celularity Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, formerly known
• Celularity Inc. Files 8-K Report — 8-K · Feb 24, 2025 Risk: low
  Celularity Inc. filed an 8-K on February 24, 2025, reporting other events and financial statements. The company, previously known as GX Acquisition Corp., is in
• Celularity Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Feb 18, 2025 Risk: medium
  Celularity Inc. entered into a material definitive agreement on February 12, 2025. The company also reported on unregistered sales of equity securities and file
• Celularity Inc. Files S-1/A Amendment — S-1/A · Feb 13, 2025 Risk: medium
  Celularity Inc. filed an S-1/A on February 13, 2025, detailing its financial performance and business operations. The company, formerly GX Acquisition Corp., is
• Celularity Inc. Files S-1 with SEC — S-1 · Jan 30, 2025 Risk: medium
  Celularity Inc. filed an S-1 form on January 30, 2025, detailing its business operations. The company, formerly GX Acquisition Corp., is in the pharmaceutical p
• Celularity Inc. Enters Material Definitive Agreement — 8-K · Jan 27, 2025 Risk: medium
  Celularity Inc. entered into a material definitive agreement on January 24, 2025. The company, formerly known as GX Acquisition Corp., is incorporated in Delawa
• Celularity Inc. Terminates Material Definitive Agreement — 8-K · Jan 24, 2025 Risk: medium
  Celularity Inc. announced on January 23, 2025, the termination of a material definitive agreement. The company, formerly known as GX Acquisition Corp., is incor
• Celularity Inc. Files 8-K for Material Agreement — 8-K · Jan 3, 2025 Risk: medium
  Celularity Inc. entered into a material definitive agreement on December 27, 2024, related to unregistered sales of equity securities. The company, formerly GX
• Celularity Inc. Holds Stockholder Meeting — 8-K · Dec 20, 2024 Risk: low
  Celularity Inc. announced on December 19, 2024, that it held a special meeting of its stockholders. The primary purpose of this meeting was to vote on proposals
• Celularity Inc. Q3 2024 Update: Agreements and Financials — 10-Q · Dec 6, 2024 Risk: medium
  Celularity Inc. reported its third-quarter financial results for the period ending September 30, 2024. The company's filing details various business activities,
• Celularity Inc. Files 8-K for Material Agreement and Equity Sales — 8-K · Dec 2, 2024 Risk: medium
  On November 25, 2024, Celularity Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on the unr
• Celularity Receives Nasdaq Delisting Warning — 8-K · Nov 29, 2024 Risk: high
  Celularity Inc. received a notice on November 21, 2024, indicating it failed to meet the continued listing rule standards for The Nasdaq Stock Market LLC. The c
• Celularity Inc. Files 2024 Proxy Statement — DEF 14A · Nov 19, 2024 Risk: low
  Celularity Inc. filed its definitive proxy statement for its 2024 Annual Meeting of Stockholders, to be held on October 19, 2024. The filing, submitted on Novem
• Celularity Inc. Files 8-K: Other Event Reported — 8-K · Nov 8, 2024 Risk: medium
  Celularity Inc. filed an 8-K on November 8, 2024, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts, or d
• Celularity Inc. Files 8-K on Financials and Other Events — 8-K · Nov 7, 2024 Risk: medium
  Celularity Inc. filed an 8-K on November 7, 2024, reporting on its financial condition and other events. The filing includes financial statements and exhibits,
• Celularity Inc. Files Q2 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Celularity Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations. Key
• Celularity Inc. Files 8-K on Financials — 8-K · Oct 25, 2024 Risk: medium
  Celularity Inc. filed an 8-K on October 25, 2024, reporting on its results of operations and financial condition as of October 22, 2024. The filing includes fin
• Celularity Faces Nasdaq Delisting Notice — 8-K · Oct 21, 2024 Risk: high
  Celularity Inc. received a notice of delisting or failure to satisfy continued listing rules from the Nasdaq Stock Market on October 18, 2024. The company is cu
• Celularity Inc. Files 8-K: Material Definitive Agreement — 8-K · Oct 16, 2024 Risk: medium
  On October 9, 2024, Celularity Inc. entered into a material definitive agreement. The company, formerly known as GX Acquisition Corp., is incorporated in Delawa
• Celularity Inc. Q1 2024 Update: Forbearance and Employment Agreements — 10-Q · Oct 16, 2024 Risk: medium
  Celularity Inc. reported its first quarter 2024 results, ending March 31, 2024. The company entered into a forbearance agreement on March 13, 2024, related to i
• Celularity CEO & Chairman Resigns, New Leadership Appointed — 8-K · Sep 13, 2024 Risk: medium
  Celularity Inc. announced on July 24, 2024, a change in its board of directors. Specifically, Dr. Robert J. Hariri has resigned from his position as Chief Execu
• Celularity Inc. Announces CEO Change and Board Appointments — 8-K · Aug 28, 2024 Risk: medium
  Celularity Inc. announced on August 27, 2024, several key executive and board changes. Dr. Robert J. Hariri has stepped down as Chief Executive Officer and will
• Celularity Inc. Faces Delisting Notice — 8-K · Aug 23, 2024 Risk: high
  Celularity Inc. received a notice on August 22, 2024, indicating it failed to meet a continued listing rule or standard for its stock. This filing is a Form 8-K
• Celularity Changes Auditors Amidst Audit Scope Disagreement — 8-K · Aug 5, 2024 Risk: medium
  Celularity Inc. announced on July 31, 2024, the departure of its independent registered public accounting firm, WithumSmith+Brown, PC. The company has appointed
• Celularity Inc. Files 2023 10-K — 10-K · Jul 30, 2024 Risk: medium
  Celularity Inc. filed its 2023 10-K on July 30, 2024, reporting on its fiscal year ending December 31, 2023. The company, formerly GX Acquisition Corp., is in t
• Celularity Faces Nasdaq Delisting Notice — 8-K · May 24, 2024 Risk: high
  Celularity Inc. received a notice on May 21, 2024, indicating it failed to meet the continued listing standards of the Nasdaq Capital Market. The company is cur

Related Companies

CELU

Frequently Asked Questions